Kestra Investment Management LLC Has $648,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kestra Investment Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 48.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 616 shares of the biopharmaceutical company’s stock after buying an additional 200 shares during the period. Kestra Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $648,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Sachetta LLC boosted its stake in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $26,000. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $33,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Citigroup started coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, November 14th. They set a “neutral” rating and a $895.00 price target for the company. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Leerink Partners reissued a “market perform” rating and set a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Royal Bank of Canada lowered their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $1,107.29.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $750.22 on Monday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $735.95 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market cap of $82.44 billion, a P/E ratio of 18.57, a price-to-earnings-growth ratio of 2.89 and a beta of 0.15. The firm’s 50-day simple moving average is $905.64 and its 200-day simple moving average is $1,019.64.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.